Vela Laboratories, a provider GMP-compliant potency and release testing, and Protagen AG, a  specialist in the characterization of protein drugs, have formed a strategic alliance in customer based analytics and marketing & sales.

“The fast-growing demand for comparability of biologics needs creative steps and business models,” said Dr. Markus Fido, chief executive officer of Vela. “Protagen and Vela are internationally renowned and well-established contract research labs for complete characterization of biopharmaceuticals and biosimilars, and both companies belong to the leading providers of ICH-compliant analytical services. Our customers will benefit from this alliance through more efficient project work and study design.”

“The technology portfolio and the exceptional expertise of VELA in the area of bioassays for potency determination of therapeutic antibodies, growth factors and protein hormones, will synergistically complement the experience and competences of Protagen. Our customers in the pharmaceutical and biotech sector, as well as CROs and CMOs, will profit from this alliance through the direct access to a comprehensive service portfolio,” said Dr. Stefan Müllner, Protagen’s chief executive officer.